Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$9.99 - $18.71 $263,236 - $493,008
-26,350 Reduced 17.23%
126,550 $2.35 Million
Q2 2023

Aug 10, 2023

BUY
$9.17 - $19.29 $69,774 - $146,777
7,609 Added 5.24%
152,900 $1.69 Million
Q1 2023

May 09, 2023

BUY
$12.53 - $21.71 $38,442 - $66,606
3,068 Added 2.16%
145,291 $1.95 Million
Q4 2022

Feb 10, 2023

BUY
$11.61 - $16.11 $70,008 - $97,143
6,030 Added 4.43%
142,223 $1.76 Million
Q3 2022

Nov 10, 2022

BUY
$12.21 - $19.7 $465,896 - $751,692
38,157 Added 38.92%
136,193 $1.9 Million
Q2 2022

Aug 05, 2022

SELL
$11.23 - $19.59 $98,902 - $172,529
-8,807 Reduced 8.24%
98,036 $1.35 Million
Q1 2022

May 12, 2022

SELL
$13.37 - $17.79 $144,208 - $191,882
-10,786 Reduced 9.17%
106,843 $1.74 Million
Q4 2021

Feb 10, 2022

SELL
$14.28 - $19.53 $6,654 - $9,100
-466 Reduced 0.39%
117,629 $1.92 Million
Q3 2021

Nov 12, 2021

SELL
$12.99 - $20.47 $24,693 - $38,913
-1,901 Reduced 1.58%
118,095 $1.75 Million
Q2 2021

Aug 12, 2021

BUY
$15.46 - $24.5 $138,382 - $219,299
8,951 Added 8.06%
119,996 $2.4 Million
Q1 2021

May 13, 2021

BUY
$19.33 - $37.75 $2.15 Million - $4.19 Million
111,045 New
111,045 $2.56 Million

Others Institutions Holding ICPT

About INTERCEPT PHARMACEUTICALS, INC.


  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.